Literature DB >> 21504968

Alteration of negatively charged residues in the 89 to 99 domain of apoA-I affects lipid homeostasis and maturation of HDL.

Andreas K Kateifides1, Irina N Gorshkova, Adelina Duka, Angeliki Chroni, Dimitris Kardassis, Vassilis I Zannis.   

Abstract

In this study, we investigated the role of positively and negatively charged amino acids within the 89-99 region of apolipoprotein A-I (apoA-I), which are highly conserved in mammals, on plasma lipid homeostasis and the biogenesis of HDL. We previously showed that deletion of the 89-99 region of apoA-I increased plasma cholesterol and phospholipids, but it did not affect plasma triglycerides. Functional studies using adenovirus-mediated gene transfer of two apoA-I mutants in apoA-I-deficient mice showed that apoA-I[D89A/E91A/E92A] increased plasma cholesterol and caused severe hypertriglyceridemia. HDL levels were reduced, and approximately 40% of the apoA-I was distributed in VLDL/IDL. The HDL consisted of mostly spherical and a few discoidal particles and contained preβ1 and α4-HDL subpopulations. The lipid, lipoprotein, and HDL profiles generated by the apoA-I[K94A/K96A] mutant were similar to those of wild-type (WT) apoA-I. Coexpression of apoA-I[D89A/E91A/E92A] and human lipoprotein lipase abolished hypertriglyceridemia, restored in part the α1,2,3,4 HDL subpopulations, and redistributed apoA-I in the HDL2/HDL3 regions, but it did not prevent the formation of discoidal HDL particles. Physicochemical studies showed that the apoA-I[D89A/E91A/E92A] mutant had reduced α-helical content and effective enthalpy of thermal denaturation, increased exposure of hydrophobic surfaces, and increased affinity for triglyceride-rich emulsions. We conclude that residues D89, E91, and E92 of apoA-I are important for plasma cholesterol and triglyceride homeostasis as well as for the maturation of HDL.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21504968      PMCID: PMC3122915          DOI: 10.1194/jlr.M012989

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  47 in total

1.  Multiple rare alleles contribute to low plasma levels of HDL cholesterol.

Authors:  Jonathan C Cohen; Robert S Kiss; Alexander Pertsemlidis; Yves L Marcel; Ruth McPherson; Helen H Hobbs
Journal:  Science       Date:  2004-08-06       Impact factor: 47.728

Review 2.  Probing the pathways of chylomicron and HDL metabolism using adenovirus-mediated gene transfer.

Authors:  Vassilis I Zannis; Angeliki Chroni; Kyriakos E Kypreos; Horng-Yuan Kan; Thais Borges Cesar; Eleni E Zanni; Dimitris Kardassis
Journal:  Curr Opin Lipidol       Date:  2004-04       Impact factor: 4.776

3.  Impaired very low density lipoprotein and triglyceride removal in broad beta disease: comparison with endogenous hypertriglyceridemia.

Authors:  A Chait; W R Hazzard; J J Albers; R P Kushwaha; J D Brunzell
Journal:  Metabolism       Date:  1978-09       Impact factor: 8.694

4.  Properties of the plasma very low and low density lipoproteins in Tangier disease.

Authors:  R J Heinen; P N Herbert; D S Fredrickson
Journal:  J Clin Invest       Date:  1978-01       Impact factor: 14.808

5.  Determination of the secondary structures of proteins by circular dichroism and optical rotatory dispersion.

Authors:  Y H Chen; J T Yang; H M Martinez
Journal:  Biochemistry       Date:  1972-10-24       Impact factor: 3.162

6.  The carboxyl-terminal hydrophobic residues of apolipoprotein A-I affect its rate of phospholipid binding and its association with high density lipoprotein.

Authors:  M Laccotripe; S C Makrides; A Jonas; V I Zannis
Journal:  J Biol Chem       Date:  1997-07-11       Impact factor: 5.157

7.  Lipid-free structure and stability of apolipoprotein A-I: probing the central region by mutation.

Authors:  Irina N Gorshkova; Tong Liu; Vassilis I Zannis; David Atkinson
Journal:  Biochemistry       Date:  2002-08-20       Impact factor: 3.162

8.  Apolipoprotein C-II deficiency syndrome. Clinical features, lipoprotein characterization, lipase activity, and correction of hypertriglyceridemia after apolipoprotein C-II administration in two affected patients.

Authors:  G Baggio; E Manzato; C Gabelli; R Fellin; S Martini; G B Enzi; F Verlato; M R Baiocchi; D L Sprecher; M L Kashyap
Journal:  J Clin Invest       Date:  1986-02       Impact factor: 14.808

9.  Molecular mechanisms of type III hyperlipoproteinemia: The contribution of the carboxy-terminal domain of ApoE can account for the dyslipidemia that is associated with the E2/E2 phenotype.

Authors:  Kyriakos E Kypreos; Xiaoping Li; Ko Willems van Dijk; Louis M Havekes; Vassilis I Zannis
Journal:  Biochemistry       Date:  2003-08-26       Impact factor: 3.162

10.  Substitutions of glutamate 110 and 111 in the middle helix 4 of human apolipoprotein A-I (apoA-I) by alanine affect the structure and in vitro functions of apoA-I and induce severe hypertriglyceridemia in apoA-I-deficient mice.

Authors:  Angeliki Chroni; Horng-Yuan Kan; Kyriakos E Kypreos; Irina N Gorshkova; Adelina Shkodrani; Vassilis I Zannis
Journal:  Biochemistry       Date:  2004-08-17       Impact factor: 3.162

View more
  3 in total

1.  Role of the hydrophobic and charged residues in the 218-226 region of apoA-I in the biogenesis of HDL.

Authors:  Panagiotis Fotakis; Andreas K Kateifides; Christina Gkolfinopoulou; Dimitra Georgiadou; Melissa Beck; Katharina Gründler; Angeliki Chroni; Efstratios Stratikos; Dimitris Kardassis; Vassilis I Zannis
Journal:  J Lipid Res       Date:  2013-08-29       Impact factor: 5.922

2.  Increased Binding of Apolipoproteins A-I and E4 to Triglyceride-Rich Lipoproteins is linked to Induction of Hypertriglyceridemia.

Authors:  Irina N Gorshkova; David Atkinson
Journal:  JSM Atheroscler       Date:  2017-02-13

3.  Binding of human apoA-I[K107del] variant to TG-rich particles: implications for mechanisms underlying hypertriglyceridemia.

Authors:  Irina N Gorshkova; Xiaohu Mei; David Atkinson
Journal:  J Lipid Res       Date:  2014-06-11       Impact factor: 5.922

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.